Conferences
ASCO GU 2024: Real-World Treatment Patterns for Patients with High-Risk Biochemically Recurrent Nonmetastatic Castration-Sensitive Prostate Cancer
January 26, 2024
ASCO GU 2024: Stockholm3 Validation in a Multi-Ethnic Cohort for Prostate Cancer (SEPTA) Detection: A Multicentered, Prospective Trial
January 26, 2024
ASCO GU 2024: Survival and Fracture Risk with Radium-223 Therapy in mCRPC: A Real-World Analysis
January 26, 2024
ASCO GU 2024: Real-world Analyses of Mortality Risk After ADT Initiation in Black vs White Patients with Prostate Cancer
January 26, 2024
ASCO GU 2024: Discussant: Androgen Deprivation & Radiation Therapy: Going Further, Together
January 26, 2024
ASCO GU 2024: Discussant: Unlocking Combination Therapy for mCRPC
January 26, 2024
ASCO GU 2024: Effect of Urinary Stagnation in the Prostatic Urethra on Generating False-Positive Midline Lesions on 18F-DCFPyL PSMA PET/CT
January 25, 2024
ASCO GU 2024: Renaming Gleason 3+3 (Grade Group 1): Against
January 25, 2024
ASCO GU 2024: Public Health Would Dramatically Improve if Gleason 6 (Grade Group 1) Weren’t Called Cancer
January 25, 2024
ASCO GU 2024: Patient-Provider Rurality and Outcomes in Older Men with Prostate Cancer
January 25, 2024
ASCO GU 2024: Systemic Treatment of High-Risk Biochemical Recurrence
January 25, 2024